Latest | Instant Finance & Market News_第350页

07:52

[ CSW Inc., World’s Largest Manufacturer of Decorative Plastic Planters, Chases the First Hong Kong Horticulture IPO ] NewTimeSpace News: CSW Inc. filed its Main Board listing application with HKEX on 25 June, with CMB International Capital Limited acting as the sole sponsor. The Group is a top-tier manufacturer and exporter of decorative gardening products, specialising in decorative plastic planters and supplying major North American mass merchandise & home improvement retailers including Lowe’s, Walmart, Sam’s Club and Costco. According to CIC Consulting, ranked by revenue in 2024 and 2025, the Company is the world’s largest manufacturer of decorative plastic planters with a 4.6% market share, and also the largest exporter among Chinese planter manufacturers.

Tag： CSW IPO file a listing application

07:47

[ WINHEALTH PHARMA Re-files HKEX Listing Application with 27 Commercialized Pharmaceutical Assets ] NewTimeSpace News: WinHealth International Holding Group Company Limited re-filed its Main Board listing application with HKEX on 25 June, with Huatai International acting as the sole sponsor. The Group is an integrated Chinese pharmaceutical enterprise focusing on renal disease treatments, boasting a diversified differentiated product portfolio covering 27 commercialized medicines plus one newly approved drug. Its therapeutic coverage centers on nephrology, extending to hematology, respiratory and dermatological disorders.

Tag： WINHEALTH PHARMA IPO refile listing application

07:42

[ NEUROGEN PHARMA Focused on Neurology, Pain Management & Allergy Files HKEX Listing Application ] NewTimeSpace News: NeuroGen Pharma Limited submitted its Main Board listing application to the Hong Kong Stock Exchange on 25 June, with JPMorgan, CICC and HSBC acting as joint sponsors. The Company is a clinical-value-driven specialty pharmaceutical platform focusing on neurology, pain management and allergy therapeutics in China. Following its acquisition of UCB’s relevant China business and assets, it has built an integrated platform anchored by well-established originator brands including Keppra®, Vimpat®, Zyrtec® and recently approved Xyzal®.

Tag： NeuroGen Pharma IPO file a listing application

22:03

[ Jiu Rong Holdings (2358.HK) Sells Five Panel Display Production Lines for RMB6.05M ] Jiu Rong Holdings (2358.HK) announced that its indirect wholly-owned subsidiary Zhejiang Jiurong Intelligent Technology entered into an asset transaction contract with independent third party Guangzhou Yingfu Technology to sell five panel display intelligent production lines and related auxiliary and testing equipment for RMB6.05 million (inclusive of tax) via public listing on the Hangzhou Property Exchange; the unaudited net book value of the assets was approximately RMB2.109 million as of December 31, 2025, with an estimated pre-tax gain of approximately RMB3.941 million, and net proceeds of approximately RMB5.354 million to be mainly used to repay outstanding loans secured by the mortgage and pledge; the Disposal is expected to complete before early July 2026 and constitutes a discloseable transaction as applicable percentage ratios exceed 5% but are below 25%; the Board believes the sale aligns with the Group's strategic shift to a light-asset operating model, enabling realization of residual value from idle assets while reducing maintenance costs and alleviating liquidity pressure.

Tag： Jiu Rong 02358.HK

21:10

[ Hengrui Medicine (01276.HK) Adebrelimab Becomes First Domestic PD-L1 Inhibitor for NSCLC Perioperative Setting ] Hengrui Medicine (1276.HK) announced three simultaneous developments on June 25, 2026: its subsidiary Shanghai Shengdi's adebrelimab injection was approved for a new NSCLC perioperative indication, becoming the first domestic PD-L1 inhibitor approved for this setting, with Phase III data showing a 53.8% MPR rate, 74.8% 2-year EFS rate and a 48% reduction in recurrence/progression/death risk, with cumulative R&D investment of approximately RMB1.225 billion; subsidiary Chengdu Shengdi's cyclosporine eye drops (IV) received marketing approval as China's first and only 0.1% anhydrous cyclosporine eye drop for dry eye, licensed from Novaliq with 17.6-fold improved bioavailability, with cumulative R&D investment of approximately RMB103 million; and HRS-4508 tablets were cleared for clinical trials in advanced solid tumors, with multiple Phase II trials underway covering breast and lung cancers, and cumulative R&D investment of approximately RMB82 million.

Tag： Hengrui Medicine 01276.HK A+H

20:53

[ DT Capital (00356.HK) Signs Strategic MOU with Laplace Lab for Decentralized Prediction Market Tech ] DT Capital (356.HK) announced it entered into a non-binding strategic cooperation memorandum with Laplace Lab Limited, the sole designated technology developer of decentralized prediction market platform SigMarket, to jointly explore decentralized prediction market technology in enterprise risk management, internal decision support and scenario analysis, including developing risk management analysis tools and AI-customized solutions; the work is limited to internal research and proof-of-concept, Laplace Lab is an independent third party, and the Board believes the cooperation will enhance internal risk management capabilities without materially affecting the Group's current year financial performance.

Tag： DT CAPITAL 00356.HK

20:49

[ Henlius (02696.HK) Serplulimab Approved by EU Commission for First-Line sqNSCLC ] Henlius (2696.HK) announced that the European Commission approved serplulimab (Hansizhuang®/HETRONIFLY®) in combination with carboplatin and nab-paclitaxel for first-line treatment of adult patients with unresectable locally advanced or metastatic sqNSCLC, applicable across all EU member states and EEA countries; the approval was based on a randomized, double-blind, international multi-center Phase 3 study showing significant benefit and good safety, following EU GMP certification in December 2023 and a positive CHMP opinion in May 2026; serplulimab is now approved in China, the EU, UK and multiple Southeast Asian countries, with the global PD-1 mAb market reaching approximately USD50.871 billion in 2025.

Tag： HENLIUS 02696.HK Innovative Drugs

20:45

[ Leads Biolabs-B (09887.HK) Partner Oblenio Closes Oversubscribed $62M Series B Led by Pfizer Ventures ] Leads Biolabs (9887.HK) announced that its joint venture with Aditum Bio, Oblenio, completed an oversubscribed $62 million Series B financing led by Pfizer Ventures with participation from Deep Track Capital, GV and Aditum Bio, to significantly advance clinical development of LBL-051, a CD19/BCMA/CD3 tri-specific T-cell engager for severe autoimmune diseases; preclinical data presented at EULAR 2026 showed complete B cell and plasma cell clearance in non-human primates without CRS, and the Company founder Dr. Kang Xiaoqiang will join Oblenio's board as an observer, with the Company entitled to milestone payments and sales royalties as the original developer.

Tag： LEADS BIOLABS-B 09887.HK

19:54

[ HJ SCIENCE-B(06132.HK) closed 38.03% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends ] By the close of trading on Jun 25, 2026, HJ SCIENCE-B(06132.HK) saw a gain of 38.03% in its share price, closing at HKD 49. During the session, it reached an intraday high of HKD 50.5 and touched an intraday low of HKD 36.

Tag： HJ Science-B 06132.HK

19:53

[ MADISON HLDG(08057.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 17.55 million, loss widened by 15.32% YoY ] June 25, 2026, MADISON HLDG(08057.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 57.9 million, decreased by 18.55% YoY

Tag： MADISON HLDG 08057.HK

19:53

[ MI MING MART(08473.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 12.46 million, YoY increase of 145.42% ] June 25, 2026, MI MING MART(08473.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 119.91 million, increased by 0.98% YoY

Tag： MI MING MART 08473.HK

19:53

[ GC CONSTRUCTION(01489.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 60.78 million, loss widened by 13.66% YoY ] June 25, 2026, GC CONSTRUCTION(01489.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 259.59 million, decreased by 51.08% YoY

Tag： GC CONSTRUCTION 01489.HK

19:53

[ TAI CHEUNG HOLD(00088.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 22 million, turned into a loss from a profit YoY ] June 25, 2026, TAI CHEUNG HOLD(00088.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 27.9 million, decreased by 22.5% YoY

Tag： TAI CHEUNG HOLD 00088.HK

19:53

[ AEON CREDIT(00900.HK): FY 26/27 Q1 Report - Profit Attributable to Shareholders stood at HKD 135.98 million, YoY increase of 24.38% ] June 25, 2026, AEON CREDIT(00900.HK) released its Q1 Report for the period ended February 28, 2027, Total Revenue stood at HKD 451.4 million, increased by 8.89% YoY

Tag： AEON CREDIT 00900.HK

19:52

[ UBA INVESTMENTS(00768.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 9.44 million, YoY decrease of 8.07% ] June 25, 2026, UBA INVESTMENTS(00768.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 3.41 million, decreased by 32.35% YoY

Tag： UBA INVESTMENTS 00768.HK

19:52

[ EDVANCE INTL(01410.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 22.41 million, YoY decrease of 8.69% ] June 25, 2026, EDVANCE INTL(01410.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 776.67 million, increased by 5.76% YoY

Tag： EDVANCE INTL 01410.HK

19:52

[ E LIGHTING(08222.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 3.27 million, turned profitable from a loss YoY ] June 25, 2026, E LIGHTING(08222.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 68.52 million, decreased by 1.75% YoY

Tag： E LIGHTING 08222.HK

19:52

[ JOHNSON HLDGS(01955.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 2.04 million, YoY decrease of 87.19% ] June 25, 2026, JOHNSON HLDGS(01955.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 3.38 billion, increased by 83.96% YoY

Tag： JOHNSON HLDGS 01955.HK

18:00

[ BAIGE ONLINE(02672.HK): Offer Price Set at HK$15.60, Trading Commences on 29 June ] NewTimeSpace News: Baige Online (Xiamen) Digital Technology Co., Ltd. (02672.HK) announced its final offer price of HK$15.60 per H Share (excluding applicable transaction charges). The Company expects trading of its H Shares to start at 9:00 a.m. on 29 June 2026 on the Main Board of HKEX, with each trading board lot comprising 200 Shares.

Tag： Baige Online 02672.HK IPO

17:34

[ SUNSHINE OIL(02012.HK): Mr. Sun Guoping Submits Required Disclosure Materials to PwC as Ordered ] NewTimeSpace News: Sunshine Oilsands Ltd. (02012.HK) announced that the Company received notice from Mr. Sun Guoping confirming that he had, by the deadline of 24 June, submitted the required disclosure materials via his legal representatives to the legal representatives of PricewaterhouseCoopers (PwC), in compliance with the Court Order dated 18 June 2026. The Company awaits further directions from the Court.

Tag： SUNSHINE OIL 02012.HK inside information